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Abstract Ubiquitin-positive tau-negative inclusions were
initially described in the rare form of frontotemporal de-
mentia (FTD) associated with motor neuron disease. How-
ever, recent studies have indicated that these inclusions
are also present in typical FTD, which is usually charac-
terized by nonspecific histological changes. To examine
the contribution of these inclusions to neuronal loss and to
explore their relationship with disease duration, we per-
formed a quantitative immunocytochemical analysis of 
38 typical FTD cases. Relationships between neuron and
ubiquitin inclusion densities as well as between duration
of illness and neuropathological parameters was studied
using linear regression in both univariate and multivariate
models. Ubiquitin-positive tau-negative intracytoplasmic
inclusions were present in 65.8% of cases in the dentate
gyrus, 57.9% in temporal cortex and 31.6% in frontal cor-
tex. The highest densities of ubiquitin-positive inclusions
were consistently observed in the dentate gyrus, followed
by the temporal and frontal cortex. There was no statisti-
cally significant relationship between neuron and ubiqui-
tin-positive inclusion densities in any of the areas studied.
In contrast, ubiquitin-positive inclusion densities in the
dentate gyrus were negatively related to the duration of
illness. Our data suggest that the development of ubiqui-
tin-related pathology is the rule and not the exception in
typical FTD, yet is not causally related to neuronal loss.
They also reveal that the development of ubiquitin-posi-
tive inclusion densities in the dentate gyrus may be asso-
ciated with a more aggressive form of the disease.
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Introduction
Frontotemporal dementia (FTD) may represent more than
20% of degenerative dementias and is currently consid-
ered as the third most common cause of degenerative de-
mentia after Alzheimer’s disease (AD) and Lewy body
dementia [32]. Although a global understanding of the
molecular background of FTD is far from being achieved,
one can schematically consider that this group includes a
large but poorly defined subgroup of typical FTD cases
characterized by nonspecific histopathological changes
(such as neuronal loss, spongiosis and gliosis), two
tauopathies [Pick’s disease and FTD and parkinsonism
linked to chromosome 17 (FTDP-17)], and one ubiquitin-
related disorder, FTD with motor neuron disease (MND)
[8, 30, 41]. This latter form is characterized clinically by
the presence of MND with dementia and neuropathologi-
cally by the formation of ubiquitin-positive and tau-nega-
tive intraneuronal inclusions in hippocampus and subcor-
tical structures [3, 7, 9, 11, 27, 31, 42, 46]. However, ubiq-
uitin-positive intraneuronal inclusions and dendrites have
also been reported in familial [6, 20, 24, 35] and in a few
sporadic FTD cases in the absence of MND [2, 15, 18, 21,
22, 36, 40, 47, 48] as well as in FTDP-17 cases [17, 28,
35]. These observations question the specificity of ubiqui-
tin-positive inclusions and their clinical relevance in the
context of FTD. To address these issues, we performed a
clinicopathological study of 38 sporadic FTD cases with-
out motor neuron symptomatology, including a quantita-
tive assessment of ubiquitin-related pathology and neu-
ronal loss in the cerebral cortex and analysis of their rela-
tionship with disease duration.
Materials and methods
The diagnoses of FTD in all cases were based on the criteria of
Lund and Manchester [5] and included progressive behavioral dis-
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order with insidious onset, affective symptoms, speech disorders,
preserved orientation and praxis and selective frontotemporal atro-
phy (CT or MRI). Spouses and first-degree relatives were inter-
viewed to complete the clinical history on the onset of symptoms.
The age at onset was defined as the age at which the first symptom
compatible with the diagnosis of FTD was observed. Since this
study focused on sporadic FTD, all cases with positive family his-
tory (at least one first-degree relative with dementia before the age
of 70 years) were excluded.
The series included 38 cases (26 women, 74.3±21.7 years old
and 12 men, 65.8±2.7 years old), who died and were autopsied at
the Psychiatric Hospital of the University of Geneva School of
Medicine, Switzerland. Demographic data are summarized in Ta-
ble 1. There were 24 early-onset cases (age at onset <65 years).
Mean age at onset was 66.5±1.9 for women and 58.6±2.9 for men.
The duration of illness ranged from 2 to 16 years (mean ± SD
7.7±0.6 years). There were no gender-related differences in dura-
tion of illness. Twenty-four patients were admitted to the hospital
with frontal lobe syndrome, including major behavioral disorders
such as disinhibition, acts of violence and eating disturbances.
Among the remaining cases, 7 presented with early speech disor-
ders leading to mutism and 8 with substantial decline of both
episodic and semantic memory. Motor neuron symptomatology 
and extrapyramidal signs were absent in each case. All cases
showed severe dementia at death (clinical dementia rating score
of 3) [14].
The brains obtained at autopsy were fixed in 15% formalin for
4 weeks and stored in 5% formalin. After macroscopic examina-
tion, both hemispheres were cut into 1-cm-thick coronal slices. For
histological and immunohistochemical purposes, tissue blocks
were taken from the inferior temporal cortex (Brodmann area 20),
frontal cortex (Brodmann area 9), hippocampus including dentate
gyrus, striatum and substantia nigra. Samples were embedded in
paraffin and cut into 14-µm-thick sections. Serial sections were
stained with hematoxylin-eosin, cresyl violet and with antibodies
against tau protein (AT8 monoclonal, 1:1,000, Innogenetics), ubiq-
uitin (polyclonal, 1:100, Sigma), and α-synuclein (monoclonal,
1:4,000, Zymed). The tissues were incubated at 4°C overnight with
antibodies against tau and ubiquitin, and for 2 nights with the anti-
body against α-synuclein. Following incubation, sections were pro-
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Table 1 Demographic and
routine neuropathological data
in the present series (n.d. not
determined, TC temporal cor-
tex, FC frontal cortex, FT fron-
totemporal)
Case Age/ Onset Duration Atrophy Gliosis Braak Ubiquitin positive
Gender (years) stage
TC FC Neurons Neurites
1 68/F 58 10 FT +++ + 1 Yes Yes
2 71/M 64 7 FT +++ + 1 Yes Yes
3 74/M 64 10 FT +++ ++ 1 Yes Yes
4 74/M 62 12 FT + + 1 No Yes
5 62/M 54 8 T + ++ 1 Yes Yes
6 62/F 53 9 FT + ++ 1 No No
7 83/F 75 13 FT ++ + 1 No Yes
8 83/F 77 6 FT + ++ 2 Yes Yes
9 64/M 53 4 F + ++ 1 Yes Yes
10 80/F 65 15 FT +++ + 1 Yes Yes
11 74/F 65 9 F + ++ 2 No Yes
12 76/F 63 13 FT +++ +++ 1 Yes Yes
13 83/F 75 8 FT +++ +++ 1 No No
14 89/F 88 11 T +++ ++ 1 Yes Yes
15 59/M 52 7 F + +++ 1 Yes Yes
16 73/F n.d. n.d. T ++ + 1 No Yes
17 62/M 51 11 T +++ ++ 1 Yes Yes
18 70/F 64 6 F +++ - 1 Yes Yes
19 81/F 77 4 T ++ - 2 Yes Yes
20 57/M 57 9 F +++ ++ 1 Yes Yes
21 83/F 78 5 T ++ + 1 No Yes
22 69/M 63 5 T +++ ++ 1 Yes Yes
23 76/F 70 6 T ++ + 2 Yes Yes
24 68/M 65 3 FT - - 1 No Yes
25 85/F 73 12 FT - - 1 No No
26 65/F 60 5 F ++ +++ 1 No Yes
27 56/F 52 4 FT +++ +++ 2 Yes Yes
28 74/F 69 5 FT - +++ 2 No No
29 83/F n.d. n.d. T ++ - 2 Yes Yes
30 48/M 38 10 F - - 1 No No
31 65/F 63 2 F - ++ 1 Yes Yes
32 58/F 51 7 T ++ ++ 1 Yes No
33 70/F 66 4 FT ++ - 1 Yes Yes
34 76/F 60 16 FT ++ - 1 Yes Yes
35 75/F 60 16 FT ++ - 1 No No
36 82/M 80 2 T +++ + 1 Yes Yes
37 81/F 79 3 T ++ + 1 Yes Yes
38 62/F 56 6 F ++ ++ 1 Yes Yes
cessed by the PAP method using 3,3′-diaminobenzidine as a chro-
mogen, as previously described [25].
Neuron and ubiquitin-positive and tau-negative intraneuronal
inclusion densities were estimated using the optical dissector, an
unbiased stereological counting method implying that all regions
within the structure of interest have an equal chance of being ana-
lyzed (i.e., there is no bias in sampling), and that counts do not de-
pend on variables such as the size and shape of neurons [12, 37,
43, 44]. The technique relies on a three-dimensional counting box
located entirely within the tissue section, and objects are quantified
by focusing in the section depth (i.e., in the z axis). The fact that
the three-dimensional counting box is located within the section
and the existence of exclusion (forbidden) planes guarantee that
each neuron is counted only once [12, 37, 43, 44]. Total cell and
neurofibrillary tangle (NFT) numbers were not obtained in the pre-
sent study due to the fact that only the anterior portion of the hip-
pocampus and only topographically equivalent samples of areas 9
and 20 were available for analysis. The volume of these samples
was variable rendering comparison of total cell numbers impossi-
ble from case to case. For this reason, neuron and ubiquitin-posi-
tive inclusion densities per mm3 were counted on 1 in 10 sections,
500 µm apart. Ten optical dissectors were placed on a random grid
covering the area of interest to provide a systematic sampling par-
adigm for each region and layer of interest. Densities were counted
using a Zeiss Axioplan microscope (×100 objective). In addition,
the presence or absence of ubiquitin-positive neurites was noted.
The presence and severity of concomitant AD pathology was de-
termined using Braak stages for NFT [4].
After normalization of the neuropathological variables, the re-
lationship between neuron densities (dependent variable) and age
and ubiquitin inclusion densities (independent variables) in each
area was studied using linear regression in both univariate and
multivariate models. For clinicopathological correlations, the asso-
ciation between duration of illness (as the dependent variable) and
neuropathological parameters (as the independent variables) was
studied using the same statistical method.
Results
Symmetrical bilateral cerebral atrophy was present in 
27 cases. A hemispheric predominance was observed in the
remaining cases (7 in left and 4 in right hemisphere). In
most cases, the cerebral atrophy was equally present in
frontal and temporal cortex. However, 9 cases showed a
predominant frontal lobe involvement, whereas in 12 cases
the temporal cortex was preferentially affected. Micro-
scopic examination revealed neuronal loss and vacuola-
tion mainly in cortical layers II and III in all cases. Mod-
erate to severe cortical gliosis was present in 26 cases in
the temporal cortex and 19 cases in the frontal cortex. All
cases showed minimal NFT formation compatible with
normal aging (31 cases with Braak stage I; 7 cases with
Braak stage II). There were no other forms of tau pathol-
ogy such as Pick bodies or glial tau inclusions nor α-sy-
nuclein-immunoreactive inclusions. Macrovascular pa-
thology such as small macroinfarcts and lacunes were ab-
sent in all cases.
Neuron and ubiquitin-positive inclusions densities in
the dentate gyrus, temporal and frontal cortex in the pre-
sent series are summarized in Table 2. Ubiquitin-positive
tau-negative intracytoplasmic inclusions were present in
25 cases (65.8%). They were most frequent in the dentate
gyrus (65.8% of cases) compared to the temporal (57.9%)
and frontal cortex (31.6%). Two types of ubiquitin inclu-
sions were observed: the “crescent-type” was mainly seen
in the neocortex, whereas the “spheric-type” was found in
the dentate gyrus (Fig. 1a, b) [19]. All these cases also dis-
played ubiquitin-positive neurites. Five other cases had
isolated ubiquitin-positive and tau-negative neurites; four
in both frontal and temporal cortex and one in the tempo-
ral cortex. The highest densities of ubiquitin-positive in-
clusions were consistently observed in the dentate gyrus,
followed by the temporal and frontal cortex. Ubiquitin-
positive neurites were consistently present in the neostria-
tum in both cases with and without cortical inclusions. In
contrast, very rare round or crescent inclusions were pre-
sent in the neostriatum only in cases with cortical inclu-
sions. Substantia nigra was free of inclusions in all cases.
There were no cases with intranuclear ubiquitin-positive
inclusions in any of the areas studied.
Regression analyses showed no significant relationship
between the neuropathological variables and age. This was
also the case between neuron and ubiquitin-positive inclu-
sion densities in the areas studied. There was a positive re-
lationship between ubiquitin-positive inclusion densities in
dentate gyrus and both temporal [regression coefficient:
5.14, 95% confidence intervals (CI): 1.47, 8.81, P<0.01]
and frontal (regression coefficient: 2.98, 95% CI: 1.19,
4.19, P<0.05) cortex. In a univariate model, ubiquitin-pos-
itive inclusion densities in the dentate gyrus were signifi-
cantly related to the duration of illness (regression coeffi-
cient: –1.03, 95% CI: –1.06, –0.86, P<0.05) (Figs. 1c–e, 2).
This association persisted in a multivariate model, which
included Braak NFT staging and age (regression coeffi-
cient: –0.75, 95% CI: –1.20, –0.37, P<0.05). Ubiquitin-
positive inclusion densities in areas 9 and 20 and neuron
densities did not correlate with the duration of illness.
Discussion
The strengths of the present study include the large series
of prospectively documented typical FTD cases, concomi-
tant assessment of neuron and ubiquitin-positive inclusion
densities and use of multivariate models for statistical analy-
sis. Our data reveal that the presence of ubiquitin-positive
tau-negative inclusions is the rule and not the exception in
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Table 2 Ubiquitin-inclusion and neuron densities (per mm3) in
the present series (DG dentate gyrus, TC temporal cortex, FC
frontal cortex)
Median 25% 75%
DG
Ubiquitin 9,996.0 0 27,988.8
Neurons 331,867.2 298,880.4 369,185.6
TC
Ubiquitin 249.9 0 999.6
Neurons 16,993.0 14,994.4 23,990.0
FC
Ubiquitin 0 0 249.9
Neurons 27,155.5 21,991.0 31,987.0
typical FTD cases. They also show that unlike neurons the
quantitative assessment of these inclusions may be a neu-
ropathological marker of disease duration.
The presence of ubiquitin-positive tau-negative intra-
neuronal inclusions within the cerebral cortex and subcor-
tical structures has been long considered as a key neu-
ropathological feature of MND with dementia [16, 45] or
FTD with MND [3, 5, 7, 9, 11, 17, 23, 27, 31, 39, 42, 46].
Despite several contributions based on small series, the
presence of ubiquitin-related pathology within the cere-
bral cortex is still considered a rare phenomenon in typi-
cal FTD cases [2, 6, 15, 18, 21, 22, 24, 34, 35, 40, 47, 48].
However, a recent population-based study of FTD in
Netherlands indicated that 25% of typical FTD cases dis-
played ubiquitin-positive inclusions [36]. Our data go be-
yond these findings in that they indicate that the appear-
ance of ubiquitin-positive inclusions and neurites is an
age-unrelated phenomenon, which occurs in the majority
of typical FTD cases mainly in the dentate gyrus of the
hippocampus and to a lesser degree in the temporal and
frontal neocortex. In conjunction with the description of
these inclusions in familial FTDP-17 cases (with or with-
out tau mutations) [17, 28, 35], our findings suggest that
the development of ubiquitin-related changes within the
cerebral cortex is not related to a specific pathogenetic
mechanism but rather represents one of the various neuro-
pathological hallmarks of FTD spectrum. In this respect,
the low percentages of neurons containing ubiquitin-posi-
tive inclusions and the absence of significant relationship
between ubiquitin-positive inclusion and neuron densities
in the present study strongly suggest that ubiquitin-related
pathology does not play a key role in the severe neuronal
loss observed in the present cases. Similar quantitative data
were obtained using the same counting methodology in a
recent morphometric study of nine familial FTD cases with
ubiquitin-positive tau-negative inclusions [6]. These ob-
servations point to the complex relationships between the
development of ubiquitin-positive inclusions and cell death
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Fig. 1 “Spheric” inclusion in the dentate gyrus (a) and “crescent”
inclusions in the superficial layer of the temporal cortex (b). Rep-
resentative examples for ubiquitin-inclusion densities as a function
of disease duration (c–e). Sections were stained with antibody
against ubiquitin (see text for details). Bar a, b 50 µm; c–e 200 µm
in FTD. Although the role of ubiquitin-positive inclusions
in this disorder is not fully understood, several recent con-
tributions suggest that their formation is related to a dys-
function of the ubiquitin proteasome system of intracellu-
lar proteolysis, which is essential for cell viability [1, 26].
In particular, an accumulation of a mutant form of the
ubiquitin-B (UBB+1) was recently reported in FTD, fur-
ther supporting an impairment of the ubiquitin-proteasome
system in this disorder [10]. However, it should be kept in
mind that the proteasome inhibition observed in neurons
containing ubiquitin-positive inclusions may induce the
activation of cell defense mechanisms, such as heat-shock
responses, ultimately leading to neuroprotection [13].
Our results also show that ubiquitin-positive inclusion
densities in the dentate gyrus were negatively related to
the disease duration. Although weak, this relationship was
robust since it persisted after controlling for age and Braak
NFT staging. The accumulation of ubiquitin-positive in-
clusions in dentate gyrus in cases with a shorter disease
duration may be a marker of a more aggressive form of
FTD. Unfortunately, all cases studied presented with se-
vere dementia (CDR score of 3) so that it was not possible
to examine further the relationship between clinical out-
come and neuropathological variables. Importantly, neu-
ron densities did not correlate with disease duration in the
present series. This finding should be interpreted in con-
junction with recent studies, which identified molecular
mechanisms surrounding neuronal loss in typical FTD. In
particular, apoptotic phenomena in both neurons and as-
trocytes [29, 33, 38] as well as a depletion of all six tau
isoforms [49] have been described in this disease, both
contributing to rapid neuronal death. It is thus likely that
neuronal loss in typical FTD cases is neither a progressive
phenomenon which would be expected to be more pro-
nounced with increased disease duration nor a marker of
disease aggressiveness.
Two main limitations should be considered when dis-
cussing our findings. First, the present series is not repre-
sentative of the whole spectrum of typical FTD cases with-
out motor neuron symptomatology since it does not in-
cludes cases with semantic dementia or primary progres-
sive aphasia. Moreover, neuron densities per cube mil-
limeter and not total neuron numbers were obtained from
the present sample. Although we used optical dissector to
limit selection biases, the absence of a rigorous stereolog-
ical design may influence the validity of clinicopatholog-
ical correlations. Future stereological studies in large au-
topsy series of well-documented FTD cases with various
degrees of clinical severity are needed to elucidate the
clinical impact of the different types of neuropathological
changes observed in this heterogeneous clinical condition.
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